Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Shabnam Jeibouei, Mohammad Esmael Akbari, Alireza Kalbasi, Amir Reza Aref, Mohammad Ajoudanian, Alireza Rezvani & Hakimeh Zali. (2019) Personalized medicine in breast cancer: pharmacogenomics approaches. Pharmacogenomics and Personalized Medicine 12, pages 59-73.
Read now
Read now
Nicole Hagner & Markus Joerger. (2010) Cancer chemotherapy: targeting folic acid synthesis. Cancer Management and Research 2, pages 293-301.
Read now
Read now
Philip Kuriakose, David R. Gandara & Edith A. Perez. (2002) Phase I Trial of Edatrexate in Advanced Breast and Other Cancers. Cancer Investigation 20:4, pages 473-479.
Read now
Read now
Godefridus J Peters & Stephen P Ackland. (1996) Leading Article: Oncologic, Endocrine & Metabolic: New antimetabolites in preclinical and clinical development. Expert Opinion on Investigational Drugs 5:6, pages 637-679.
Read now
Read now
Articles from other publishers (33)
Galal H. Elgemeie & Reham A. Mohamed-Ezzat. 2022. New Strategies Targeting Cancer Metabolism. New Strategies Targeting Cancer Metabolism
143
220
.
Tianfeng Gao, Congying Zhang, Xiaowei Shi, Ran Guo, Kai Zhang, Jianmin Gu, Lin Li, Shuolei Li, Qianqian Zheng, Mengyu Cui, Miao Cui, Xingmei Gao, Yi Liu & Lei Wang. (2019) Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents. European Journal of Medicinal Chemistry 178, pages 329-340.
Crossref
Crossref
SarahA Mubaraki. (2019) Oral mucositis in children associated with hematopoietic stem cells transplant. Saudi Journal of Oral Sciences 6:2, pages 47.
Crossref
Crossref
Balaraman Selvakumar & Kuppanagounder P. Elango. (2019)
Synthesis of Non-Glutamate-Type Pyrrolo[2,3-d]Pyrimidines via Direct Aminocarbonylation of Aryl Halides Using Solid Co
2
(CO)
8
as a CO Source and Their Antibacterial Activity
. Journal of Chemical Research 41:4, pages 230-234.
Crossref
Crossref
Douglas E. Peterson, Kerstin ?hrn, Joanne Bowen, Monica Fliedner, Judith Lees, Charles Loprinzi, Takehiko Mori, Anthony Osaguona, Dianna S. Weikel, Sharon Elad & Rajesh V. Lalla. (2012) Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Supportive Care in Cancer 21:1, pages 327-332.
Crossref
Crossref
Ana Maria Gonzalez-Angulo, Flavia Morales-Vasquez & Gabriel N. Hortobagyi. 2007. Breast Cancer Chemosensitivity. Breast Cancer Chemosensitivity
1
22
.
Jackie Walling. (2006) From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Investigational New Drugs 24:1, pages 37-77.
Crossref
Crossref
W. Thomas Purcell & David S. Ettinger. (2003) Novel antifolate drugs. Current Oncology Reports 5:2, pages 114-125.
Crossref
Crossref
Gerardo Colon-Otero, Robert D. Niedringhaus, Shauna H. Hillman, Susan Geyer, Jeffrey Sloan, James E. Krook, Harold E. Windschitl, Randolph S. Marks, Martin Wiesenfeld, Loren K. Tschetter & James J. Jett. (2001) A Phase II Trial of Edatrexate, Vinblastine, Adriamycin, Cisplastin, and Filgrastim (EVAC/G-CSF) in Patients With Non?Small-Cell Carcinoma of the Lungs. American Journal of Clinical Oncology 24:6, pages 551-555.
Crossref
Crossref
Larry H. Matherly. 2001.
131
162
.
Andre Rosowsky, Joel E. Wright, Chitra M. Vaidya, Ronald A. Forsch & Henry Bader. (2000)
Analogues of the Potent Nonpolyglutamatable Antifolate
N
α
-(4-Amino-4-deoxypteroyl)-
N
δ
-hemiphthaloyl-
l
-ornithine (PT523) with Modifications in the Side Chain,
p
-Aminobenzoyl Moiety, or 9,10-Bridge: Synthesis and in Vitro Antitumor Activity
. Journal of Medicinal Chemistry 43:8, pages 1620-1634.
Crossref
Crossref
Richard Gorlick. 2000. Methotrexate. Methotrexate
9
29
.
Hedy L. Kindler, Chandra P. Belani, James E. Herndon, Nicholas J. Vogelzang, Yasunosuke Suzuki & Mark R. Green. (1999) Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Cancer 86:10, pages 1985-1991.
Crossref
Crossref
J.R. Rigas, M.G. Kris, V.A. Miller, K.M.W. Pisters, R.T. Heelan, S.C. Grant, D.W. Fennelly, Ting-Chao Chou & F.M. Sirotnak. (1999) Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. Annals of Oncology 10:5, pages 601-603.
Crossref
Crossref
Richard Gorlick & Joseph R. Bertino. 1999. Antifolate Drugs in Cancer Therapy. Antifolate Drugs in Cancer Therapy
37
57
.
Julio Barredo, Marlene A. Bunni, Raghunathan Kamasamudram & David G. Priest. 1999. Antifolate Drugs in Cancer Therapy. Antifolate Drugs in Cancer Therapy
323
337
.
Frederick J. Meyers, Danika Lew, Primo N. LaraJr.Jr., Steve Williamson, Ernest Marshall, Stanley P. Balcerzak, Saul E. Rivkin, Wolfram Samlowski & E. David Crawford. (1998) Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124). Investigational New Drugs 16:4, pages 347-351.
Crossref
Crossref
Martin J. Edelman, David R. Gandara, Edith A. Perez, Derrick Lau, Ignacio Lauder, Corrine Turrell, Margaret Uhrich & Frederick Meyers. (1998) Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Investigational New Drugs 16:1, pages 69-75.
Crossref
Crossref
Gerrit Jansen & Rob Pieters. (1998) The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates. Drug Resistance Updates 1:3, pages 211-218.
Crossref
Crossref
Jacques Galipeau, Ely Benaim, Harold T. Spencer, Raymond L. Blakley & Brian P. Sorrentino. (1997) A Bicistronic Retroviral Vector for Protecting Hematopoietic Cells Against Antifolates and P-Glycoprotein Effluxed Drugs. Human Gene Therapy 8:15, pages 1773-1783.
Crossref
Crossref
Robert Dreicer, Kathleen J. Propert, Timothy Kuzel, John M. Kirkwood, Peter J. O'Dwyer & Patrick J. Loehrer. (1997) A Phase II Trial of Edatrexate in Patients with Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology 20:3, pages 251-253.
Crossref
Crossref
Martina C. Hum & Barton A. Kamen. (1996) Folate, antifolates, and folate analogs in Pediatric Oncology. Investigational New Drugs 14:1, pages 101-111.
Crossref
Crossref
Chris H. Takimoto. (1996) New Antifolates: Pharmacology and Clinical Applications. The Oncologist 1:1-2, pages 68-81.
Crossref
Crossref
Michael J. Spinella, Kevin E. Brigle, Esteban E. Sierra & I. David Goldman. (1995) Distinguishing between Folate Receptor-α-mediated Transport and Reduced Folate Carrier-mediated Transport in L1210 Leukemia Cells. Journal of Biological Chemistry 270:14, pages 7842-7849.
Crossref
Crossref
Colin Paul Spears. (1995) Clinical Resistance to Antimetabolites. Hematology/Oncology Clinics of North America 9:2, pages 397-414.
Crossref
Crossref
Ting-Chao Chou, Glenys M. Otter & Francis M. Sirotnak. (1995) Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemotherapy and Pharmacology 37:3, pages 222-228.
Crossref
Crossref
George deStevens, V. Zingel, C. Leschke, W. Schunack, Paul D. Hoeprich, Richard M. Schultz, P. K. Mehrotra, Sanjay Batra, A. P. Bhaduri, Anil K. Saxena & Mridula SaxenaRichard M. Schultz. 1995. Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques
129
157
.
Colin Paul Spears, Göran Carlsson, Franco M. Muggia, George Jaresko & Bengt G. Gustavsson. 1995. Concepts, Mechanisms, and New Targets for Chemotherapy. Concepts, Mechanisms, and New Targets for Chemotherapy
115
134
.
R. Pazdur, D.F. Moore, B. Bready, L. Giannone, A. Maldonado, Y.G. Lin, R.H. Fueger, R.J. Winn & B. Levin. (1994) Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma. Annals of Oncology 5:7, pages 646-648.
Crossref
Crossref
Jeffrey S. Abrams, Timothy D. Moore & Michael Friedman. (1994) New chemotherapeutic agents for breast cancer. Cancer 74:S3, pages 1164-1176.
Crossref
Crossref
D.F. MooreJrJr, R. Pazdur, J.L. Abbruzzese, J.A. Ajani, D.W. Dubovsky, J.L. WadeIIIIII, R.J. Belt, C. Mangold, B. Bready & R.J. Winn. (1994) Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Annals of Oncology 5:3, pages 286-287.
Crossref
Crossref
Jacques Jolivet, Gerrit Jansen, Godefridus J. Peters, Marie-France Pinard & Jan H. Schornagel. (1994) Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate. Biochemical Pharmacology 47:4, pages 659-665.
Crossref
Crossref
Edith A. Perez, Frank M. Hack, Lauri M. Webber & Ting-Chao Chou. (1993) Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. Cancer Chemotherapy and Pharmacology 33:3, pages 245-250.
Crossref
Crossref